Engineered nanoparticles could deliver better targeted cancer treatment to lymph nodes

Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver cancer immunotherapy that caused fewer side effects compared to standard treatment in a preclinical study. The work is published in the journal Proceedings of the National Academy of Sciences.